Biogen Inc.
BIIB
#779
Rank
$32.664 B
Marketcap
United States
Country
$221.07
Share price
8.43%
Change (1 day)
51.28%
Change (1 year)
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an…
Key Metrics
Trailing P/E
38.15
Forward P/E
12.98
EPS (TTM)
$5.63
Forward EPS
$16.54
Price / Book
1.68
EV / EBITDA
11.7x
Beta
0.17
Dividend Yield
—
Return on Equity
4.58%
Return on Assets
5.21%
Debt / Equity
44.33
Current Ratio
1.86
Gross Margin
78.32%
Operating Margin
25.06%
Net Profit Margin
8.32%
Free Cash Flow
$1.267B
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 17 – Sep 15
+2.71%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$9.891B
Latest Net Income$1.293B
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Biogen Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
BIIB
No recent news available. Set FINNHUB_API_KEY to enable news.
